Marpai, Inc.
No enriched coverage for $MRAI in the last 7 days.
No SEC Form 4 filings for $MRAI in the last 30 days.
See all $MRAI insider activity →Marpai, Inc. (OTCQX: MRAI) reported Q2 2026 results for the three and six months ended June 30, 2026. Revenue fell to $8.6 million for six months ended June 30, 2026 from $10.1 million a year earlier. The company cited faster cost reductions improving gross margin, and amended debt maturities to 2028 and 2029. After quarter-end, it raised $12.1 million via a private placement.
Marpai, Inc. (MRAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Marpai Announces $12 Million Private Placement led by Mitchell Companies Tampa, Florida — July 29, 2026 — Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administration (“TPA”), and Pharmacy Benefit Ma
Marpai, Inc. (OTCQX: MRAI) said it completed securities purchase agreements for a $12 million private placement of newly designated convertible preferred stock led by Mitchell Companies. The deal sold 12,100 shares at $1,000 each with a $1.00 initial conversion price. Preferred holders receive an 8% dividend in common shares and convert on a liquidity event or qualified public offering.
Recent MRAI coverage spans insider activity, corporate actions and market movers.
Turnaround progress plus balance-sheet actions (debt extensions and new preferred financing) should support downside risk, but revenue contraction and low cash remain key overhangs.
The filing signals a new equity financing (Series A Preferred) with defined minimum and maximum proceeds, which can dilute common holders and affect near-term capital structure expectations.
The financing strengthens Marpai’s capital position and introduces dilution and dividend mechanics tied to conversion/liquidity events.
The AXA amendment improves near-term liquidity and reduces required debt service timing, lowering near-term cash pressure for MRAI.
Insider sale to issuer (buyback/repurchase participation) is disclosed without price, offering limited signal on fundamentals but may affect near-term sentiment.
alphai scores every news story that mentions MRAI with an AI model for sentiment and relevance, and aggregates insider trades from Marpai, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Marpai, Inc. (OTCQX: MRAI) reported Q2 2026 results for the three and six months ended June 30, 2026. Revenue fell to $8.6 million for six months ended June 30, 2026 from $10.1 million a year earlier. The company cited faster cost reductions improving gross margin, and amended debt maturities to 2028 and 2029. After quarter-end, it raised $12.1 million via a private placement.
5 min readMarpai, Inc. (MRAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Marpai Announces $12 Million Private Placement led by Mitchell Companies Tampa, Florida — July 29, 2026 — Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administration (“TPA”), and Pharmacy Benefit Ma
6 min readMarpai, Inc. (OTCQX: MRAI) said it completed securities purchase agreements for a $12 million private placement of newly designated convertible preferred stock led by Mitchell Companies. The deal sold 12,100 shares at $1,000 each with a $1.00 initial conversion price. Preferred holders receive an 8% dividend in common shares and convert on a liquidity event or qualified public offering.
4 min readMarpai, Inc. (MRAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001844392 0001844392 2026-07-16 2026-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readEITAN YARON sold (to issuer) 50,000 shares of Marpai, Inc. (MRAI) on 2025-12-08.
1 min readJohnson Steve Andrew (Chief Financial Officer) purchased 1,100 shares of Marpai, Inc. (MRAI) at $0.62 on 2026-06-02.
2 min readSHIV SAGIV sold (to issuer) 50,000 shares of Marpai, Inc. (MRAI) on 2025-12-08 under a Rule 10b5-1 trading plan.
2 min readPONS ROBERT M sold (to issuer) 50,000 shares of Marpai, Inc. (MRAI) on 2025-12-08.
2 min read
